{"id":17877,"date":"2020-08-03T08:37:09","date_gmt":"2020-08-03T08:37:09","guid":{"rendered":"https:\/\/celonpharma.com\/?p=17877"},"modified":"2020-08-03T08:37:09","modified_gmt":"2020-08-03T08:37:09","slug":"results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/","title":{"rendered":"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine"},"content":{"rendered":"

\u00a0Results of the PI3K delta study developed by Celon Pharma \u2013 CPL302-253 \u2013 have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma <\/em><\/a>\u00a0presents the results of the development of a preclinical, highly specific and safe PI3K delta inhibitor \u2013 inhalation drug candidate in asthma and COPD.<\/p>\n

The authors concluded that the molecule has not only therapeutic, but also preventive potential \u2013 due to its proven safety in asthma treatment. It is currently the only PI3K delta inhibitor developed in the form of an inhalant used in asthma and COPD therapy. PLOs is one of the most recognised open access journals, which publishes the results of basic and preclinical studies. Its articles are reviewed by over 3,000 scientists from around the world.<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0Results of the PI3K delta study developed by Celon Pharma \u2013 CPL302-253 \u2013 have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma \u00a0presents the results of the development of a preclinical, highly specific and safe PI3KRead more »<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-17877","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"\nResults of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"\u00a0Results of the PI3K delta study developed by Celon Pharma \u2013 CPL302-253 \u2013 have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma \u00a0presents the results of the development of a preclinical, highly specific and safe PI3KRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-03T08:37:09+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/\",\"url\":\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/\",\"name\":\"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2020-08-03T08:37:09+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/","og_locale":"en_US","og_type":"article","og_title":"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP","og_description":"\u00a0Results of the PI3K delta study developed by Celon Pharma \u2013 CPL302-253 \u2013 have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma \u00a0presents the results of the development of a preclinical, highly specific and safe PI3KRead more »","og_url":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/","og_site_name":"CelonGROUP","article_published_time":"2020-08-03T08:37:09+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/","url":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/","name":"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2020-08-03T08:37:09+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celon.group\/en\/2020\/08\/03\/results-of-the-pi3k-delta-study-developed-by-celon-pharma-in-the-prestigious-plos-magazine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/17877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=17877"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/17877\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=17877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=17877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=17877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}